Ashley Regazzi

11PUBLICATIONS
94CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 02, 2026
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.

Brendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran

|Dec 01, 2025
Automated Imaging as an Adjunct to Serum and Clinical Biomarkers: A New Validated Prediction Tool for Metastatic Castration-Resistant Prostate Cancer.

Michael J Morris, Jessica Flynn, Binsheng Zhao

|Jul 01, 2025
Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601.

Gopa Iyer, Woonyoung Choi, Bin Luo

|Jun 16, 2025
Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research.

Michal Sternschuss, Michael Lattanzi, Emily Vertosick

|Nov 05, 2024
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial.

Gopa Iyer, Catherine M Tangen, Michal Sarfaty

|Sep 08, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.

Brendan J Guercio, Michal Sarfaty, Min Yuen Teo

Pageof 2

Frequent Collaborators

9 joint publications

Jonathan E Rosenberg

9 joint publications

Gopa Iyer

8 joint publications

Hikmat Al-Ahmadie

8 joint publications

Samuel A Funt